{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Binomial test against a null"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.4","upperLimit":"53.3","value":"43.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"ORR is the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) based on CT scans evaluated by IRC per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group D"}],"paramType":"NUMBER","populationDescription":"Evaluable for CT-based Response Set (all dosed and central pathology confirmed Peripheral T Cell Lymphoma (PTCL) patients with baseline measurable disease assessed by IRC using CT imaging)","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part B: CT-based Objective Response Rate (ORR) by Independent Review Committee (IRC)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}